Form SC 13D Sarepta Therapeutics, Filed by: Barry Richard
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Baird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward
May 6, 2015 6:10 AM EDTBaird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable risk/reward into FDA guidance.
Analyst Brian Skorney commented, "We're jumping back into the stock after last week's NDA submission by potential competitor... More
Sarepta Therapeutics (SRPT) New Board Member Rick Barry Files 13D
May 5, 2015 3:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is active after Rick Barry filed a 13D showing a 7.66% stake, or 3,165,014. Rick Barry has been nominated to join the Board of Directors of the Issuer, Sarepta Therapeutics, and has accepted the nomination.
SI NOTE: Barry has been a... More
